Book:LIMS Buyer’s Guide for Cannabis Testing Laboratories/Cannabis testing and research: An overview/Why test?

From LIMSWiki
Jump to navigationJump to search

1.3 Why test?

CCE by Draconis- laboratory work on plant essences and cannabinoid material.jpg

The attempts to legalize, regulate, and standardize cannabis, cannabis products, and all the activities surrounding the industry are apparent, but why is laboratory testing of cannabis important? Why test?

First, from a purely research-based perspective, analytical testing of cannabis helps society learn more about the plant and its constituents, and how they positively and negatively affect human health when ingested. Though research has been difficult to accomplish in the U.S. over the years[1], the long-term lack of understanding about the plant and its effects of use continues to push researchers forward to expand that societal understanding.[2][3] Granted, some countries such as Israel have been at the forefront of cannabis research and testing, with researchers there receiving funding from U.S. companies, as well as the U.S. government.[4][5] Studies and clinical trials from Israeli researchers on autism[6] and inflammatory bowel disease[7], as well as the agricultural[8][9], analytical[10], and broad medical aspects of the plant[11] continue to move the science forward for everyone. With a new administration steering the helm in the U.S. in 2021, a promise of prioritizing "the research needed to advance science-based federal policies related to the use of marijuana for medical conditions, chronic pain, and disabilities"[12] remains to be seen, though some in the cannabis industry appear to be cautiously optimistic.[13][14]

Second, similar to how we have mechanisms like laboratory testing in place to ensure the safety of medicines, foods, beverages, and cosmetics for human use, we should be performing similar testing for the human and animal use of cannabis and cannabis-related products. Microbes, heavy metals, pesticides, and solvents that are dangerous to consume—particularly for medical marijuana patients with fragile and weak immune systems—must be identified and quantified through quality control in order to protect public health.[15][16][17] Without quality testing and safety oversight, cannabis products can cause sickness or even death.[18]

Third, growers and sellers of cannabis and cannabis-related products should be held accountable for the claims they make about their products. When growers, sellers, and even the testing laboratories themselves are held accountable, consumer confidence can be gradually built.[17] This can be difficult, however, given a lack of a federal regulatory framework for both THC-containing and low-THC/high-CBD products. For example, independent testing in 2020 of CBD-containing products found an abysmally low 13 percent of products tested matched their label claims, findings similar to those of a 2020 FDA market survey.[19] Law firm Keller and Heckman warn that "buyers need to be cautious" concerning the purchase of largely unregulated CBD products[19], which highlights the difficulty of improving consumer confidence in the face of little regulation. However, most U.S. states that have legalized some form of cannabis have also mandated laboratory testing, not only for the two prior reasons but also to hold accountable those producers and sellers supplying the legal cannabis market with products containing specific cannabinoid amounts.[17][20]

When considering these three points, it's easier to understand the "why" of testing. But what gets tested and how? The next chapter addresses this question, as well as the workflows surrounding the "how."

References

  1. National Academies of Sciences, Engineering, and Medicine (2017). "Challenges and Barriers in Conducting Cannabis Research". The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press. doi:10.17226/24625. ISBN 9780309453073. 
  2. McKeil, J. (5 June 2020). "Cannabis Research - The Researchers Paving the Way". Cannabis Tech. https://www.cannabistech.com/articles/cannabis-researchers-paving-the-way/. Retrieved 07 July 2021. 
  3. Jaeger, K. (2 July 2020). "Congress Votes To Let Researchers Study Marijuana From Dispensaries". Marijuana Moment. https://www.marijuanamoment.net/congress-votes-to-let-researchers-study-marijuana-from-dispensaries/. Retrieved 07 July 2021. 
  4. Schwartz, Y. (11 April 2017). "The Holy Land of Medical Marijuana". https://www.usnews.com/news/best-countries/articles/2017-04-11/israel-is-a-global-leader-in-marijuana-research. Retrieved 07 July 2021. 
  5. Smith, N. (26 September 2019). "Cannabis research pioneer hopes latest discovery is not overlooked — again". NBC News. https://www.nbcnews.com/tech/innovation/cannabis-research-pioneer-hopes-latest-discovery-not-overlooked-again-n1059116. Retrieved 07 July 2021. 
  6. Schelider, L.B.-L.; Mechoulam, R.; Saban, N. et al. (2019). "Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy". Scientific Reports 9: 200. doi:10.1038/s41598-018-37570-y. PMC PMC6336869. PMID 30655581. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336869. 
  7. Picardo, S.; Kaplan, G.G.; Sharkey, K.A. et al. (2019). "Insights into the role of cannabis in the management of inflammatory bowel disease". Therapeutic Advances in Gastroenterology 12: 1–13. doi:10.1177/1756284819870977. PMC PMC6727090. PMID 31523278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727090. 
  8. Duchin, S.; Bernstein, N.; Kamenetsky, R. et al. (2020). "New insights on flowering of Cannabis sativa". Acta Horticulturae 1283: 17–20. doi:10.17660/ActaHortic.2020.1283.3. 
  9. Hadad, L.; Luria, N.; Smith, E. et al. (2019). "Lettuce Chlorosis Virus Disease: A New Threat to Cannabis Production". Viruses 11: 802. doi:10.3390/v11090802. 
  10. Berman, P.; Futoran, K.; Lewitus, G.M. et al. (2018). "A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis". Scientific Reports 8: 14280. doi:10.1038/s41598-018-32651-4. PMC PMC6155167. PMID 30250104. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155167. 
  11. Zarhin, D. (2020). The trajectory of “medical cannabis” in Israel: Driving medicalization in different directions. 82. 102809. doi:10.1016/j.drugpo.2020.102809. PMID 32516686. 
  12. Jaeger, K. (29 May 2020). "Joe Biden’s New Disability Plan Includes Boosting Medical Marijuana Research". Marijuana Moment. https://www.marijuanamoment.net/joe-bidens-new-disability-plan-includes-boosting-medical-marijuana-research/. Retrieved 07 July 2021. 
  13. Sacirbey, O. (24 December 2020). "DEA might start issuing cannabis cultivation permits in early 2021". Marijuana Business Daily. https://mjbizdaily.com/dea-might-start-issuing-marijuana-cultivation-permits-in-early-2021/. Retrieved 07 July 2021. 
  14. Koehn, E. (19 January 2021). "Pot stocks riding high on Biden optimism". The Sydney Morning Herald. https://www.smh.com.au/business/small-business/pot-stocks-riding-high-on-biden-optimism-20210119-p56v5c.html. Retrieved 07 July 2021. 
  15. Shaffer, C. (1 August 2019). "Medical Cannabis Poses Unique Testing Challenges". Genetic Engineering & Biotechnology News. https://www.genengnews.com/insights/medical-cannabi-poses-unique-testing-challenges/. Retrieved 07 July 2021. 
  16. Maddox, N. (Spring 2017). "Into the Weeds: Cannabis Testing and Public Health Labs". Lab Matters. Association of Public Health Laboratories. https://www.aphl.org/aboutAPHL/publications/lab-matters/Pages/into-the-weeds.aspx. Retrieved 07 July 2021. 
  17. 17.0 17.1 17.2 Brown, R. (9 November 2020). "False test results, lab shopping put cannabis consumers at risk". Marijuana Business Daily. https://mjbizdaily.com/false-lab-results-lab-shopping-put-cannabis-consumers-at-risk/. Retrieved 07 July 2021. 
  18. Montoya, Z.; Conroy, M.; Heuvel, B.D.V. et al. (2020). "Cannabis Contaminants Limit Pharmacological Use of Cannabidiol". Frontiers in Pharmacology 11: 571832. doi:10.3389/fphar.2020.571832. PMC PMC7516211. PMID 33013414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516211. 
  19. 19.0 19.1 Keller and Heckman (2020). "Independent Testing of Well-Known Beverages Provides Further Evidence of CBD Products Not Meeting Label Claims for Cannabidiol Content". The National Law Review 10 (237). https://www.natlawreview.com/article/independent-testing-well-known-beverages-provides-further-evidence-cbd-products-not. 
  20. Peña, J. (25 September 2018). "Why marijuana infused businesses have experienced testing and labeling challenges in California". Marijuana Business Daily. https://mjbizdaily.com/why-marijuana-infused-businesses-have-experienced-testing-and-labeling-challenges-in-california/. Retrieved 07 July 2021. 


-----Go to the next chapter of this guide-----

Citation information for this chapter

Chapter: 1. Cannabis testing and research: An overview

Edition: Summer 2021

Title: LIMS Buyer’s Guide for Cannabis Testing Laboratories

Author for citation: Shawn E. Douglas

License for content: Creative Commons Attribution-ShareAlike 4.0 International

Publication date: August 2021